392 G (Carbidopa and levodopa extended release 25 mg / 100 mg)
Pill imprint 392 G has been identified as Carbidopa and levodopa extended release 25 mg / 100 mg.
Carbidopa/levodopa is used in the treatment of parkinson's disease; neuroleptic malignant syndrome; restless legs syndrome; gtp-ch deficiency and belongs to the drug class dopaminergic antiparkinsonism agents. Risk cannot be ruled out during pregnancy. Carbidopa/levodopa 25 mg / 100 mg is not subject to the Controlled Substances Act.
See also related documents.
Images for 392 G (Carbidopa and levodopa extended release 25 mg / 100 mg)
- 25 mg / 100 mg
- Elliptical / Oval
- Prescription only
- Drug Class:
- Dopaminergic antiparkinsonism agents
- Pregnancy Category:
- C - Risk cannot be ruled out
- CSA Schedule:
- N - Not a controlled drug
- Global Pharmaceuticals
- National Drug Code (NDC):
- Inactive Ingredients:
- hydroxypropyl cellulose
FD&C Blue No. 2
FD&C Red No. 40
Carbidopa and levodopa extended release is associated with the treatment of:
Search by Imprint, Shape or Color
Note: All fields are optional. Use the pill finder to identify medications by visual appearance or name. All Rx and OTC drugs in the US are required by the FDA to have an imprint. If your pill has no imprint it could be a vitamin, diet/herbal/energy pill, illicit or foreign drug. More about imprint codes...